SAN DIEGO--(BUSINESS WIRE)--Sequenom, Inc. (NASDAQ:SQNM) today announced a significant step in the development of a noninvasive test for Trisomy 21, Down syndrome, that will incorporate multiple RNA fetal markers, including the PLAC4 gene as previously published by Dr. Dennis Lo, Chinese Hong Kong University.
